IRLAB Therapeutics AB (IRLABa)

Currency in SEK
3.165
-0.195(-5.80%)
Closed·
IRLABa Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
3.1653.550
52 wk Range
3.16518.500
Key Statistics
Prev. Close
3.36
Open
3.55
Day's Range
3.165-3.55
52 wk Range
3.165-18.5
Volume
234.65K
Average Volume (3m)
79.15K
1-Year Change
-80.88%
Book Value / Share
0.09
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IRLABa Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

IRLAB Therapeutics AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

IRLAB Therapeutics AB Company Profile

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson’s disease and other CNS disorders. The company develops Mesdopetam that is in phase IIb clinical studies for the treatment of levodopa-induced dyskinesia; and Pirepemat, which is in phase IIb clinical trial indicated for the treatment of falls frequency, postural dysfunction, cognitive function, and symptoms of Parkinson’s disease. Its preclinical stage products include IRL942 research programs for the treatment of cognitive deficits in Parkinson’s and other neurological disorders; IRL757 to treat apathy in neurological diseases; and IRL1117, a drug candidate developed oral treatment for the hallmark symptoms of Parkinson’s. In addition, the company develops P003, a research project that discovers and develops dopamine D1 and D2 receptor agonist compounds for the treatment of Parkinson’s core motor symptoms. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is headquartered in Gothenburg, Sweden.

Employees
30
Market
Sweden

Compare IRLABa to Peers and Sector

Metrics to compare
IRLABa
Peers
Sector
Relationship
P/E Ratio
−2.2x0.0x−0.5x
PEG Ratio
−0.040.000.00
Price/Book
36.7x0.0x2.6x
Price / LTM Sales
1.7x0.0x3.2x
Upside (Analyst Target)
-0.0%40.5%
Fair Value Upside
Unlock0.0%4.4%Unlock

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.65 / --
Revenue / Forecast
8.10M / --
EPS Revisions
Last 90 days

IRLABa Income Statement

FAQ

What Stock Exchange Does IRLAB Therapeutics Trade On?

IRLAB Therapeutics is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for IRLAB Therapeutics?

The stock symbol for IRLAB Therapeutics is "IRLABa."

What Is the IRLAB Therapeutics Market Cap?

As of today, IRLAB Therapeutics market cap is 164.16M.

What Is IRLAB Therapeutics's Earnings Per Share (TTM)?

The IRLAB Therapeutics EPS (TTM) is -1.51.

When Is the Next IRLAB Therapeutics Earnings Date?

IRLAB Therapeutics will release its next earnings report on 26 Aug 2025.

From a Technical Analysis Perspective, Is IRLABa a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has IRLAB Therapeutics Stock Split?

IRLAB Therapeutics has split 2 times.

How Many Employees Does IRLAB Therapeutics Have?

IRLAB Therapeutics has 30 employees.

What is the current trading status of IRLAB Therapeutics (IRLABa)?

As of 25 Jul 2025, IRLAB Therapeutics (IRLABa) is trading at a price of 3.17, with a previous close of 3.36. The stock has fluctuated within a day range of 3.17 to 3.55, while its 52-week range spans from 3.17 to 18.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.